Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07799922

IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus

Sponsor: Tianjin Medical University Cancer Institute and Hospital

View on ClinicalTrials.gov

Summary

This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumor thrombus who have received three cycles of target-immunotherapy induction and have non-progressive disease will be enrolled. All patients must be considered unresectable or unable to tolerate surgical resection by MDT review and must provide written informed consent. Participants will be randomized 2:1. Forty patients will undergo open or percutaneous IRE followed by continuation of the original target-immunotherapy regimen; twenty patients will continue the original treatment regimen alone. OS, PFS, tumor response, QoL, safety, and postoperative outcomes will be observed.

Official title: A Prospective, Randomized Controlled Phase II Clinical Study of Sequential or Non-sequential Irreversible Electroporation After Targeted Immunotherapy Induction in Patients With Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-05-20

Completion Date

2028-12-31

Last Updated

2026-09-02

Healthy Volunteers

Conditions

IRE

Interventions

OTHER

IRE

undergo open or percutaneous IRE followed by continuation of the original target-immunotherapy regimen

OTHER

PLACEBO

the original treatment regimen alone

Inclusion Criteria: * Age 18-75 years, any sex * Imaging-confirmed or histologically confirmed primary liver cancer/hepatocellular carcinoma (HCC) * After three cycles of target-immunotherapy induction, MDT review determines unresectable disease or inability to tolerate surgical resection * Willingness to receive standard conversion treatment * No prior palliative targeted immunotherapy or other systemic antitumor therapy * Maximum tumor diameter \<=5 cm and number of tumors \<=5 * No extrahepatic metastasis; portal vein tumor thrombus Vp1-3 * At least one measurable lesion according to RECIST 1.1 * Adequate organ and marrow function: hemoglobin \>=9.0 g/dL; neutrophils \>=1.5 x 10\^9/L; platelets \>=100 x 10\^9/L; TBIL \<=3 x ULN; AST and ALT \<=5.0 x ULN; serum creatinine \<=1.5 x ULN or CrCl \>60 mL/min by Cockcroft-Gault formula * ECOG Performance Status 0-1 * Expected survival of at least 3 months * Patients of childbearing potential and their partners agree to use contraception * Voluntary written informed consent Exclusion Criteria: * Refusal to receive systemic therapy or possible surgery * Metastasis to other sites, such as lymph nodes, peritoneum, lung, bone, or brain * History of other malignancies, except cured basal cell carcinoma of the skin or cervical carcinoma in situ * Severe uncontrolled comorbidities, including uncontrolled congestive heart failure (NYHA III/IV), unstable angina, poorly controlled arrhythmia, uncontrolled hypertension, active infection, uncontrolled diabetes, uncontrolled pleural effusion/pericardial effusion/ascites requiring drainage, severe portal hypertension or portal cavernoma on imaging, gastric outlet obstruction, or respiratory insufficiency requiring oxygen * Major surgery within 30 days before screening * EGFR monoclonal antibody or EGFR-TKI within 30 days before screening * Allergy to any drug or component used in this protocol * Known or self-reported HIV infection or chronic hepatitis B or hepatitis C * Unresolved toxicity \>=CTCAE grade 2 from prior treatment, except anemia, alopecia, skin pigmentation, or chemotherapy-induced neurotoxicity * Any other reason judged by the investigator to make participation inappropriate

Locations (1)

Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, China